Harpoon's prodrug TriTAC, termed ProTRiTAC, are T-cell engagers that are designed to activate once it is in close proximity to the tumor. Moreover, TriTACs are designed to be "off the shelf", which will streamline the manufacturing as well as the dosing procedure. TriTACs are expected to sustain their activity despite depressed levels of antigen expression and are not dependent on MHC expression. TriTACs are basically a bispecific bonded to an HSA antibody that permits extended stability, which will help preserve efficacy without the requirement for frequent dosing. Harpoon is attempting to improve this class of therapies by addressing their stability and half-life in the patient's blood. With 3 TriTACs in the clinic, along with their pre-clinical assets, Harpoon has the potential to build out a broad pipeline covering numerous oncology indications. Harpoon Therapeutics is an immunotherapy biotech company that utilizes their TriTAC, ProTriTAC, and TriTAC-XR platforms to discover "off-the-shelf" T-cell engagers that help T-cells eliminate solid tumors and hematologic cancers. Finally, I discuss how I intend to initiate a position in HARP and will reveal my strategy for managing that position in the second half of 2022.
In addition, I provide my views on Harpoon and its investment opportunity. I intend to present some background on Harpoon and the company's platform technology. After some deliberation, I determined that HARP is a candidate for the Bio Boom portfolio thanks to the ticker's valuation and the company's upside potential. It only took a couple of minutes of performing some due diligence for me to remember my initial research into Harpoon following its IPO in 2019 and my interest in the company's TriTAC platform potential. Harpoon Therapeutics (HARP) popped up on my radar after scanning for small-cap healthcare tickers that have a negative enterprise value "EV". Over the past few weeks, I have been on the lookout for speculative plays that have been beaten down during the recent selloff and have met the criteria to be in the Compounding Healthcare "Bio Boom" portfolio. I am looking to initiate a small position under $2.00 per share in order to take advantage of the current negative EV valuation. Therefore, HARP is a Compounding Healthcare speculative "Bio Boom" candidate. This does raise concerns about the company’s platform, and the rest of their pipeline programs.
Harpoon discontinued the development of their lead asset, HPN424. HARP was not immune to the biotech selloff and popped up on my radar after scanning for small-cap healthcare tickers that have a negative enterprise value. The company has several catalysts for its pipeline of four clinical assets this year that can validate the TriTAC platform. Their “off-the-shelf” T-cell engagers help T-cells eliminate solid tumors and hematologic cancers. Harpoon Therapeutics has an intriguing platform that can generate stable bispecific immunotherapies using their TriTAC technology. Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
0 kommentar(er)
